Antiphospholipid syndrome: a clinical review

Veronica Mezhov, Julian D. Segan, Huyen Tran, Flavia M. Cicuttini

Research output: Contribution to journalReview ArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti-β2-glycoprotein 1 and anticardiolipin). It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis). Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications. The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications. If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis. Antithrombotic treatment is gold standard and effective.

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalThe Medical Journal of Australia
Volume211
Issue number4
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Anticoagulants
  • Autoimmune diseases
  • Lupus erythematosus, systemic
  • Review article
  • Thromboembolism

Cite this